Ask Warren

L&K Biomed

156100 · KOSDAQ · ₩156100 · 엘앤케이바이오

₩5,800▼ ₩470 (7.50%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩12B₩9.5B₩8.6B₩10B₩11B₩8.9B₩10B₩9.7B
Cost of sales₩1.9B₩1.3B₩1.6B₩1.7B₩1.8B₩1.6B₩1.9B₩1.8B
Gross profit₩9.8B₩8.2B₩7B₩8.4B₩9.6B₩7.3B₩8.2B₩7.9B
Operating income₩1.3B₩106M−₩1.2B₩338M₩1.7B−₩145M₩569M₩1.3B
Net income₩8B₩7.9B−₩16B₩2.6B−₩2.3B−₩734M₩5.8B−₩827M
Net income to shareholders₩7.6B₩8.3B−₩16B₩2.7B−₩2.6B−₩605M₩6.3B−₩1.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩110B₩112B₩83B₩82B₩80B₩85B₩83B₩78B
Current assets₩87B₩87B₩61B₩60B₩61B₩65B₩64B₩57B
Cash and equivalents₩4.6B₩9B₩3.2B₩4.8B₩5.2B₩4.3B₩3.8B₩4.9B
Total liabilities₩53B₩60B₩45B₩40B₩43B₩48B₩47B₩45B
Current liabilities₩46B₩53B₩38B₩33B₩36B₩40B₩39B₩37B
Borrowings₩26B₩25B₩16B₩20B₩22B₩23B₩22B₩20B
Total equity₩57B₩52B₩39B₩43B₩37B₩37B₩36B₩33B
Shareholders' equity₩64B₩59B₩45B₩49B₩43B₩44B₩42B₩38B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩45M−₩1.2B−₩2.1B−₩1.3B−₩6.3B−₩4.2B₩1B−₩1.6B
Capital spending₩690M₩2.9B₩545M₩802M₩940M₩704M₩94M₩249M
Free cash flow−₩735M−₩4B−₩2.6B−₩2.1B−₩7.2B−₩4.9B₩914M−₩1.9B

Consolidated where available. Amounts in won.

Also known as: L&K Biomed / 엘앤케이바이오 / 156100 / KRX:156100

Source: KRX statistical information